Elizabeth Klumpp

Pennsylvania

Group Editorial Director, Oncology at Haymarket Media

horses, family, nature, dogs, cats, friends, and things I otherwise find interesting (I promise not to post pictures of my meals)

Featured in: Favicon

haymarket.com Favicon

cancertherapyadvisor.com Favicon

oncologynurseadvisor.com Favicon

infectiousdiseaseadvisor.com Favicon

pulmonologyadvisor.com Favicon

hematologyadvisor.com

Articles

Acalabrutinib Plus Axi-Cel Appears Safe, Effective for B-Cell Lymphoma

Mar 12, 2024 | hematologyadvisor.com | Elizabeth Klumpp

Combination treatment with acalabrutinib and axicabtagene ciloceucel (axi-cel) produced durable responses and was considered well tolerated in a phase 1/2 trial of patients with relapsed or refractory B-cell lymphoma. Results from this trial were presented at Tandem Meetings 2024. The trial (ClinicalTrials.gov Identifier: NCT04257578) included 18 patients who had diffuse large B-cell lymphoma (n=14), follicular lymphoma (n=3), or primary mediastinal B-cell lymphoma (n=1).
Data Support Earlier COVID-19 Vaccination After HSCT, CAR T-Cell Therapy

Mar 8, 2024 | medicalbag.com | Elizabeth Klumpp

New data appear to support earlier use of COVID-19 vaccines in patients who have received a hematopoietic stem cell transplant (HSCT) or chimeric antigen receptor (CAR) T-cell therapy. Researchers found that patients who were vaccinated 3-4 months after HSCT or CAR T-cell therapy had similar humoral and T-cell responses as patients who were vaccinated at 4-12 months after cellular therapy. The findings suggest “there’s not much benefit to waiting,” said Joshua A.
Data Support Earlier COVID-19 Vaccination After HSCT, CAR T-Cell Therapy

Mar 8, 2024 | hematologyadvisor.com | Elizabeth Klumpp

New data appear to support earlier use of COVID-19 vaccines in patients who have received a hematopoietic stem cell transplant (HSCT) or chimeric antigen receptor (CAR) T-cell therapy. Researchers found that patients who were vaccinated 3-4 months after HSCT or CAR T-cell therapy had similar humoral and T-cell responses as patients who were vaccinated at 4-12 months after cellular therapy. The findings suggest “there’s not much benefit to waiting,” said Joshua A.
Data Support Earlier COVID-19 Vaccination After HSCT, CAR T-Cell Therapy

Mar 1, 2024 | infectiousdiseaseadvisor.com | Elizabeth Klumpp

New data appear to support earlier use of COVID-19 vaccines in patients who have received a hematopoietic stem cell transplant (HSCT) or chimeric antigen receptor (CAR) T-cell therapy. Researchers found that patients who were vaccinated 3-4 months after HSCT or CAR T-cell therapy had similar humoral and T-cell responses as patients who were vaccinated at 4-12 months after cellular therapy. The findings suggest “there’s not much benefit to waiting,” said Joshua A.
Acalabrutinib Plus Axi-Cel Appears Safe, Effective for B-Cell Lymphoma

Feb 29, 2024 | cancertherapyadvisor.com | Elizabeth Klumpp

Combination treatment with acalabrutinib and axicabtagene ciloceucel (axi-cel) produced durable responses and was considered well tolerated in a phase 1/2 trial of patients with relapsed or refractory B-cell lymphoma. Results from this trial were presented at Tandem Meetings 2024. The trial (ClinicalTrials.gov Identifier: NCT04257578) included 18 patients who had diffuse large B-cell lymphoma (n=14), follicular lymphoma (n=3), or primary mediastinal B-cell lymphoma (n=1).
Data Support Earlier COVID-19 Vaccination After HSCT, CAR T-Cell Therapy

Feb 26, 2024 | cancertherapyadvisor.com | Elizabeth Klumpp

New data appear to support earlier use of COVID-19 vaccines in patients who have received a hematopoietic stem cell transplant (HSCT) or chimeric antigen receptor (CAR) T-cell therapy. Researchers found that patients who were vaccinated 3-4 months after HSCT or CAR T-cell therapy had similar humoral and T-cell responses as patients who were vaccinated at 4-12 months after cellular therapy. The findings suggest “there’s not much benefit to waiting,” said Joshua A.
US Lung Cancer Incidence and Mortality on the Decline, Disparities Remain

Feb 9, 2024 | oncologynurseadvisor.com | Elizabeth Klumpp

US lung cancer incidence and mortality rates have declined in recent years, but there are wide variations between the sexes and across racial and ethnic groups, according to data published in Cancer. The population‐based data come from the National Cancer Institute, the US Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries.
US Lung Cancer Incidence and Mortality on the Decline, Disparities Remain

Feb 8, 2024 | pulmonologyadvisor.com | Elizabeth Klumpp

US lung cancer incidence and mortality rates have declined in recent years, but there are wide variations between the sexes and across racial and ethnic groups, according to data published in Cancer. The population‐based data come from the National Cancer Institute, the US Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries.
US Lung Cancer Incidence and Mortality on the Decline, Disparities Remain

Feb 7, 2024 | cancertherapyadvisor.com | Elizabeth Klumpp

US lung cancer incidence and mortality rates have declined in recent years, but there are wide variations between the sexes and across racial and ethnic groups, according to data published in Cancer. The population‐based data come from the National Cancer Institute, the US Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries.